Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from LTR Pharma Limited ( (AU:LTP) ).
LTR Pharma reported strong progress in the December quarter, highlighted by SPONTAN surpassing 1,000 prescriptions under Australia’s TGA Special Access Scheme, providing valuable real-world data in higher-need erectile dysfunction patients and guiding the company’s clinical, regulatory and commercial strategy. The company also advanced its SPONTAN Phase II pharmacokinetic trial with ethics and TGA clearance and initial dosing underway, while keeping ROXUS on track for a planned US market launch in the first half of 2026 via the 503(a) personalised medicine pathway; supported by a A$25.9 million cash balance and an increased strategic stake in omega-3 specialist LevOmega, LTR Pharma is strengthening its pipeline, commercial infrastructure and broader men’s health positioning.
More about LTR Pharma Limited
LTR Pharma Limited is an ASX-listed biopharmaceutical company focused on men’s health, developing and commercialising innovative nasal spray treatments for erectile dysfunction. Its lead products, SPONTAN and ROXUS, target patients with complex or difficult-to-treat ED, with SPONTAN currently used under Australia’s TGA Special Access Scheme and ROXUS being prepared for personalised medicine distribution in the US via men’s health clinics and telehealth channels.
Average Trading Volume: 323,245
Technical Sentiment Signal: Buy
Current Market Cap: A$103.6M
For a thorough assessment of LTP stock, go to TipRanks’ Stock Analysis page.